The expression of CXCR4 in human brain tumors and the potent anti-xenograft activity of the selective CXCR4 antagonists AMD 3100 and AMD 3465 position CXCR4 among the few validated targets for molecular therapy of malignant brain tumors [127,171]. This evidence concerns the gene CXCR4 and brain cancer.